AI Science Tracker
EN

An interpretable machine learning model for predicting response to anti-GD2 combined with umbilical cord blood-derived natural killer cell immunotherapy in neuroblastoma.

School of Electronics and Information Engineering, Wuyi University, China; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, China; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Department of Anesthesiology, Sun Yat-sen University Cancer Center, China; Institute of Intelligent Manufacturing, Guangdong Academy of Sciences, China; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, China · 29 Oct 2026 · medicine

Discovery

An interpretable machine learning model for predicting response to anti-GD2 combined with umbilical cord blood-derived natural killer cell immunotherapy in neuroblastoma.

Source check: Source checked. Not independent scientific confirmation.

Finding: serial peripheral-blood data from 42 patients, dynamic coupling features, seven models with repeated stratified cross-validation; L2 logistic model AUC .873 (bootstrap CI .735–.976), Brier .131. Authors explicitly require larger independent validation.

Technology: Model-enabled response prediction within 42-patient treatment cohort; exploratory cross-validation, not evidence therapy efficacy

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Model-enabled response prediction within 42-patient treatment cohort; exploratory cross-validation, not evidence therapy efficacy.
Test and result
serial peripheral-blood data from 42 patients, dynamic coupling features, seven models with repeated stratified cross-validation; L2 logistic model AUC .873 (bootstrap CI .735–.976), Brier .131. Authors explicitly require larger independent validation. Evaluation: Methods/Results: serial peripheral-blood data from 42 patients, dynamic coupling features, seven models with repeated stratified cross-validation; L2 logistic model AUC .873 (bootstrap CI .735–.976), Brier .131.
Limitation / still unknown
The 42-patient result is exploratory and internally cross-validated; the authors call for larger independent validation, and treatment benefit was not tested.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1940534/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.